3 recruiting. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 3 |
Follow Busulfan test dose: new trials by email Literature Review of Busulfan test dose trials Research Report on Busulfan test dose
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome Allogeneic HSCT, Busulfan test dose, Mycophenolate mofetil (MMF) - Immunodeficiency, Hematopoietic Stem Cell Transplantation | Phase 2 | Recruiting | National Cancer Institute (NCI) | 54 | 2023-02-23 | 2026-10-16 |
| Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity Busulfan test dose, Fludarabine, Busulfan - Lymphoproliferative Disorders, Autoimmune Lymphoproliferative | Phase 2 | Recruiting | National Cancer Institute (NCI) | 66 | 2020-09-22 | 2026-11-12 |
| Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations Allogeneic HSCT, Busulfan Test dose, Fludarabine (Fludara, Berlex Laboratories) - GATA2, Immunodeficiency | Phase 2 | Recruiting | National Cancer Institute (NCI) | 144 | 2013-07-24 | 2026-10-16 |
Autoimmune Diseases (2) · Immunologic Deficiency Syndromes (2) · Anemia, Refractory, with Excess of Blasts (1) · Common Variable Immunodeficiency (1) · Immune System Diseases (1) · Lymphoproliferative Disorders (1) · Myelodysplastic Syndromes (1) · Opportunistic Infections (1) · T cell immunodeficiency primary (1)
National Cancer Institute (NCI) (3)
United States (3)
Bhavisha A Patel, M.D. (1) · Danielle E Pregent-Arnold, M.D. (1) · Sung-Yun Pai, M.D. (1)
PMID 32556286, PMID 36251488, PMID 37595058, PMID 41175032, PMID 41370196